|
Products |
| Products |
|
Diseases |  |
News |  |
| «12...910111213141516171819...39313932» |
- Darzalex (daratumumab) / J&J
Immunomodulatory Effects of Daratumumab on the Bone Marrow Microenvironment in Multiple Myeloma: Insights from Single-Cell Analyses (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_487;
Our comprehensive single-cell analyses unveil distinct immunomodulatory effects of Dara on the bone marrow immune microenvironment, including alterations in immune cell frequencies, activation states, and functional pathways. The observed upregulation of senescence markers, immune checkpoints, and pro-tumoral pathways in relapsed patients highlights potential resistance mechanisms and suggests avenues for therapy combination and sequencing strategies to enhance efficacy, overcome resistance, and improve patient outcomes in MM.
- Sarclisa (isatuximab-irfc) / Sanofi
MRD tracking in blood using a de novo sequencing from SPEP gel of M-protein in Multiple Myeloma Patients (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_471;
P1
Identical M-protein sequenced from the gel and directly from serum demonstrates the specificity and robustness of M-inSight in serum. The separation in gel allows an alternative sample preparation for M-protein sequencing.
- Darzalex (daratumumab) / J&J
Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_467;
The separation in gel allows an alternative sample preparation for M-protein sequencing. This study highlights the factors that contribute to the reappearance of MRD in transplant-eligible NDMM patients and emphasizes the importance of early attainment of MRD-negative status and maintenance therapy options to maintain long-term MRD negativity.
- Darzalex (daratumumab) / J&J
DARATUMUMAB AS CONSOLIDATION THERAPY IN MULTIPLE MYELOMA PATIENTS IN >VGPR/MRD POSITIVE AFTER FIRST LINE THERAPY: FINAL ANALYSIS OF THE MULTICENTRIC PHASE 2 STUDY DART4MM (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_463;
Dara is efficacious as consolidation/eradication therapy given 6 to 24 months in multiple myeloma patients already achieving >VGPR but MRD pos by NGF. About a third of patients do achieve long term MRD neg status.
- Darzalex (daratumumab) / J&J
Serum BLYS and soluble (sBCMA) levels in Multiple Myeloma (MM) patients (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_460;
Levels of sBCMA levels remained increased all over the course of the disease. Indeed, we can not say if the levels were increased or decreased, since BCMA is cleaved from the cell surface.
- Tecvayli (teclistamab-cqyv) / Genmab, J&J
Dengue fever in Multiple Myeloma patients: clinical characteristics and outcomes (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_451;
The diagnosis and management are challenging and needs high suspicion in cases without classical symptoms such as fever. Support treatment still seems to offer good outcomes.
- Talvey (talquetamab-tgvs) / J&J
Oral Symptom Assessment using Patient Reported Outcomes (PRO) for Relapsed Multiple Myeloma Patients treated with Talquetamab (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_438;
Oral specific PROs demonstrated a significant worsening of oral symptoms, global health status with Tal by week 2 followed by an improvement in global health status. Oral symptoms improved by 3 months in those stopping.
- Real World Single Centre Experience On The Use of Radiotherapy In The Treatment of Patients with Multiple Myeloma (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_432;
An important observation was the low incidence of repeat irradiation at previous RT sites, suggesting the radiosensitive nature of MM. RT could continue to hold a role in patients who become refractory to systemic therapy as salvage bridging therapy especially in the era of CAR-T and BsAbs.
- Darzalex (daratumumab) / J&J
Daratumumab treatment in the patients' own home. (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_426;
Administration of daratumumab by a district nurse is safe, feasible, timesaving, and preferred by the patients. PRO data can effectively evaluate patients prior to treatment.
- Tecvayli (teclistamab-cqyv) / Genmab, J&J, Talvey (talquetamab-tgvs) / J&J
Treatment Outcomes of Primary vs. Referred Patients with Multiple Myeloma Receiving Talquetamab or Teclistamab (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_413;
PRO data can effectively evaluate patients prior to treatment. Results suggest partnerships between academic and community providers can expand access of novel therapies to underserved, rural patients without increased toxicity or compromised patient outcomes.
- Sarclisa (isatuximab-irfc) / Sanofi
An orthopedic consultation and exercise intervention in patients with multiple myeloma during induction therapy: the randomized controlled GMMG-HD8-INDEX trial (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_407;
Our first results indicate that an exercise intervention based on an orthopedic evaluation of bone stability is safe during induction therapy for patients with newly-diagnosed MM. However, patients need to be monitored closely and exercise plans should be adapted to individual clinical conditions.
- Darzalex (daratumumab) / J&J
Guillain-Barr (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_406;
We present the case of a 65-year-old patient with a previous history of ischemic heart disease, treated for a lambda light chain ISS1 MM who achieved VGPR after 4 induction cycles of daratumumab-bortezomib-lenalidomide-dexamethasone, but who complained of bortezomib-induced sensory polyneuropathy. This case underscores a rare autoimmune neurological complication of stem cell transplantation, prompting inquiries into diagnosis, appropriate management, especially in highly immunocompromised patients, and presenting confounding factors.
- Darzalex (daratumumab) / J&J, Cytovene (ganciclovir) / Roche
GASTROINTESTINAL HISTOPLASMOSIS IN A PATIENT WITH MULTIPLE MYELOMA AFTER AUTOLOGOUS BONE MARROW TRANSPLANTATION: ORAL ULCER DIFFERENTIAL DIAGNOSIS. CASE REPORT. (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_405;
We report a case of gastrointestinal histoplasmosis infection in a Myeloma patient after autologous stem cell transplant and DVD treatment. Thus, we recall the attention for the importance of histoplasmosis suspicion as a differential diagnosis in patients undergoing stem cell transplant and possibly the impact of new immunotherapies for MM treatment.
- Talvey (talquetamab-tgvs) / J&J
Updated Comparative Effectiveness of Talquetamab vs Real-world Physician's Choice of Treatment in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_397;
P1
Thus, we recall the attention for the importance of histoplasmosis suspicion as a differential diagnosis in patients undergoing stem cell transplant and possibly the impact of new immunotherapies for MM treatment. With longer follow-up, tal at QW and Q2W dosing schedules continued to show superior effectiveness across all efficacy endpoints vs RWPC in pts with TCE RRMM.
- Talvey (talquetamab-tgvs) / J&J
Long-Term Efficacy and Safety Results From the Phase 1/2 MonumenTAL-1 Study of Talquetamab, a GPRC5D (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_396;
P1, P2
The safety profile was consistent with previous reports. These data support tal as a versatile treatment for pts with RRMM.
- Carvykti (ciltacabtagene autoleucel) / J&J
Patient-Reported Outcomes in the Phase 3 CARTITUDE-4 Study of Ciltacabtagene Autoleucel Vs Standard of Care in Patients With Lenalidomide-Refractory Multiple Myeloma After 1 (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_394;
P3
These data support tal as a versatile treatment for pts with RRMM. Introduction: The phase 3 CARTITUDE-4 trial (NCT04181827) in patients (pts) with lenalidomide (len)
- Elrexfio (elranatamab-bcmm) / Pfizer, Tecvayli (teclistamab-cqyv) / Genmab, J&J, Talvey (talquetamab-tgvs) / J&J
Impact of granulocyte colony-stimulating factor exposure on cytokine release syndrome during bispecific antibody initiation in relapsed/refractory multiple myeloma (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_393;
Exposure to GCSF during BsAb initiation was not significantly associated with increased risk of CRS. These results suggest that there are no major safety concerns with GCSF administration for neutropenia during BsAb initiation, although larger cohorts are needed to confirm these findings.
- Actemra IV (tocilizumab) / Roche, JW Pharma, Tecvayli (teclistamab-cqyv) / Genmab, J&J, Talvey (talquetamab-tgvs) / J&J
Real World Data on Bispecific Antibodies in the Brazilian Setting (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_391;
BsAbs will be used as a mainstay treatment for most of the Brazilian patients for whom it is available. Responses and the toxicity profile seem to be in line with what was previously observed in pivotal studies, although more data and follow-up are necessary for definitive conclusions.
- Talvey (talquetamab-tgvs) / J&J
Talquetamab versus Belgian real-world clinical practice in triple-class exposed relapsed and refractory multiple myeloma patients using adjusted comparison. (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_389;
Responses and the toxicity profile seem to be in line with what was previously observed in pivotal studies, although more data and follow-up are necessary for definitive conclusions. Both talquetamab 0.4 mg/kg weekly and 0.8 mg/kg Q2W showed superior effectiveness compared to RWCP treatments administered for each measure of clinical effectiveness in Belgian TCE RRMM pts and indicate its potential as a novel and effective treatment in TCE RRMM pts.
- Carvykti (ciltacabtagene autoleucel) / J&J
Infections and Immune Reconstitution in the Phase 3 CARTITUDE-4 Trial of Ciltacabtagene Autoleucel vs Standard Care in Patients with Lenalidomide-Refractory Multiple Myeloma (MM) and 1 (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_388;
P3
Both talquetamab 0.4 mg/kg weekly and 0.8 mg/kg Q2W showed superior effectiveness compared to RWCP treatments administered for each measure of clinical effectiveness in Belgian TCE RRMM pts and indicate its potential as a novel and effective treatment in TCE RRMM pts. Cilta-cel arm pts underwent apheresis, received bridging tx (daratumumab-pomalidomide-dexamethasone [DPd]/pomalidomide-bortezomib-dexamethasone [PVd]), and then cilta-cel infusion 5
- Tecvayli (teclistamab-cqyv) / Genmab, J&J
Impact of COVID-19 on Outcomes With Teclistamab in the Phase 1/2 MajesTEC-1 Study in Patients With Relapsed/Refractory Multiple Myeloma (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_387;
Survival with teclistamab in MajesTEC-1 was longer when censored for COVID-19 deaths. More data from pts treated with teclistamab in the era of both innate and vaccine-induced immunity are needed to further understand the impact of COVID-19 on outcomes.
- Abecma (idecabtagene vicleucel) / BMS, 2seventy bio, Tecvayli (teclistamab-cqyv) / Genmab, J&J
Evaluating T-cell fitness pre B-cell maturation antigen (BCMA)-targeted T-cell redirection therapies (TRT) as a predictive marker for efficacy/toxicity in relapsed/refractory multiple myeloma (RRMM) (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_386;
One limitation was a small sample size and thus testing PSI in a larger cohort might yield a statistically significant correlation and more granular data on T-cell profiles for each TRT. The NR group had more high-risk cytogenetics and higher EM.
- Tecvayli (teclistamab-cqyv) / Genmab, J&J, Talvey (talquetamab-tgvs) / J&J
Real-World Clinical Outcomes of Teclistamab and Talquetamab in Relapsed/Refractory Multiple Myeloma (RRMM): A UK Single-Centre Experience (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_385;
In terms of outcomes, in our experience teclistamab showed lower response rates and durability compared to trial data (possibly biased by the characteristics of our cohort), while talquetamab exhibited higher response rates and promising durability. These findings emphasize the importance of further real-world data with larger samples to overcome the main weakness of our study and obtain robust evidence to complement clinical trials and optimize strategies for RRMM.
- Tecvayli (teclistamab-cqyv) / Genmab, J&J
Clinical Outcomes of Teclistamab among MajesTEC-1 Eligible and Ineligible Population in the Real-World Setting for the Treatment of Relapsed/Refractory Multiple Myeloma (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_384;
In pts who would not have met TEC-1 eligibility, despite significant disease burden and high-risk features, the unadjusted ORR still appears to be comparable with TEC-1 trial. Updated findings with longer follow-up and larger sample size are warranted and will be presented at the meeting.
- Tecvayli (teclistamab-cqyv) / Genmab, J&J, Talvey (talquetamab-tgvs) / J&J
Simultaneous Progressive Multifocal Leukoencephalopathy and BK Virus-nephropathy associated with Bispecific Antibody Therapy in Multiple Myeloma (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_382;
It has been readily demonstrated that T cell dysfunction is key in the development of polyomavirus infections. JC virus-specific CD8+ cytotoxic T cells are commonly detected in the blood of PML survivors and are notably absent in those with fatal disease within one year.
- Talvey (talquetamab-tgvs) / J&J
TALQUETAMAB, A GPRC5DXCD3 BISPECIFIC ANTIBODY, FOR TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA IN PATIENTS WITH PRIOR EXPOSURE TO BCMA TARGETED THERAPIES - A "REAL WORLD" STUDY (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_380;
The response rates observed in our "real-world" setting are comparable to those of the pivotal trial. The safety profile remains favorable, marked by low occurrence of CRS and ICANS as well as manageable burden of infectious toxicities.
- Sequencing of Bispecific Antibodies in Relapsed Refractory Multiple Myeloma (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_379;
The safety profile remains favorable, marked by low occurrence of CRS and ICANS as well as manageable burden of infectious toxicities. To date, 3 BsAB have been approved for RRMM, two of which
- Talvey (talquetamab-tgvs) / J&J
Real-World Safety and Efficacy of Talquetamab for Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_378;
To date, 3 BsAB have been approved for RRMM, two of which In this real-world experience of the safety and efficacy of talquetamab for RRMM, results were comparable to that of the MonumenTAL-1 trial even though 50% of patients would not have been eligible.
- Talvey (talquetamab-tgvs) / J&J
Prompt and Profound Responses with Talquetamab in Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_377;
Patients receiving talquetamab after leukapheresis for either idecabtagene vicleucel or ciltacabtagene autoleucel therapy, but before CAR T infusion were included. This study demonstrates rapid and profound responses to talquetamab, with no patients exhibiting disease progression or new end organ damage, providing an option for bridge to CART.
- Actemra IV (tocilizumab) / Roche, JW Pharma, Talvey (talquetamab-tgvs) / J&J
Prophylactic Tocilizumab to Mitigate Cytokine Release Syndrome in Patients Receiving Talquetamab for Relapsed/Refractory Multiple Myeloma: Results From the Phase 1/2 MonumenTAL-1 Study (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_376;
P2
No neutropenia, a common side effect of toci, and no increase in rates of infection were observed. These data support the exploration of outpatient administration of tal priming doses to reduce the burden of hospitalization during initial tal treatment.
- forimtamig (RG6234) / Roche
Development of a Quantitative Systems Pharmacology (QSP) model describing T-cell bispecific induced immune activation and Multiple Myeloma (MM) cell killing (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_374;
P1
It may therefore be utilized to predict response in virtual populations at different dosing regimens and for different patient subgroups. This example illustrates that in-silico modeling of T cell-engaging bispecific antibody MoA may support more accurate dose finding in Phase 1 studies.
- Actemra IV (tocilizumab) / Roche, JW Pharma, Tecvayli (teclistamab-cqyv) / Genmab, J&J
Longer-Term Follow-Up of Patients Receiving Prophylactic Tocilizumab for Cytokine Release Syndrome in the Phase 1/2 MajesTEC-1 Study of Teclistamab in Relapsed/Refractory Multiple Myeloma (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_373;
P2
No new safety signals or impact on response to teclistamab was observed with longer follow-up. Prophylactic toci may be a useful measure to consider when selecting pts for outpatient administration of teclistamab in the future.
- Tecvayli (teclistamab-cqyv) / Genmab, J&J
Real-World Experience with Teclistamab for Relapsed/ Refractory Multiple Myeloma from the U. S. Myeloma Immunotherapy Consortium (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_370;
The real-world safety and efficacy of teclistamab is comparable to that observed among both BCMA-unexposed and BCMA-exposed patients on MajesTEC-1. Though response rates were lower in BCMA-exposed patients, PFS was similar to BCMA-unexposed patients among those achieving ?VGPR.
- Safety Profiles of Novel Myeloma Therapies: A Comprehensive FAERS Analysis (Q1 2020 - Q1 2024) (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_369;
In heavily treated patients with advanced disease, Elranatamab and Teclistamab exhibited high rate of hospitalizations, and deaths. These observatiions are most likely suggestive for selection bias as many of these patients are sick and require urgent treatments.
- Tecvayli (teclistamab-cqyv) / Genmab, J&J
Long-Term Follow-Up From the Phase 1/2 MajesTEC-1 Trial of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_366;
With the longest follow-up of any BsAb in MM, teclistamab continues to demonstrate deep and durable responses, including in pts who switch to less frequent dosing. The safety profile of teclistamab remains consistent with that of BCMA-targeted bispecific therapies, with a notable decrease in new onset of severe infections with time.
- Talvey (talquetamab-tgvs) / J&J
Prophylactic Interventions for Oral Toxicities With the GPRC5D (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_365;
Pts will be randomized to 1 of 4 cohorts: 1 control cohort and 3 experimental cohorts receiving the following prophylaxis: dexamethasone mouthwash, oral pregabalin, or clonazepam orally dissolving tablets. This study will provide needed data on smell- and taste-related assessment tools; potential strategies to manage, prevent, and decrease the severity of tal-related oral toxicities; and assessments of the potential impact of toxicities on pt treatment experience.
- Tecvayli (teclistamab-cqyv) / Genmab, J&J
Effectiveness and safety of teclistamab in triple-class exposed relapsed/refractory multiple myeloma: results of the French real-world RetrosTECtive study. (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_364;
In our real-world experience, effectiveness and safety of teclistamab seem comparable to those of the original MajesTEC-1 trial. Data of the whole cohort will be presented at the meeting.
- Tecvayli (teclistamab-cqyv) / Genmab, J&J
Trial in Progress: A Retrospective Multi-Country Study of Clinical Outcomes in Patients with R/R Multiple Myeloma Treated with Teclistamab Outside of Clinical Trials (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_363;
Information on the management and outcomes of these patients is limited. Hence, this study will provide valuable data in RRMM patients treated in early access programs and early commercial phases to complement data from clinical trials and potentially inform future management of teclistamab by the medical community.
- cevostamab (RG6160) / Roche, Darzalex (daratumumab) / J&J, Talvey (talquetamab-tgvs) / J&J
Ferritin Dynamics are Associated with Clinical Outcomes of Multiple Myeloma Patients Receiving Bispecific Antibodies (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_358;
Moreover, 36 (18.2%) received a BiAb with daratumumab, pomalidomide, or both, and 164 (82.8%) received the RP2D... Our study highlights that patients with higher ferritin at baseline and during BiAb therapy demonstrate less favorable outcomes, suggesting ferritin as a potential prognostic biomarker for BiAb therapy in MM.
- Talvey (talquetamab-tgvs) / J&J
Cytokine Release Syndrome in Patients Receiving Alternative Step-Up Doses of Talquetamab for Relapsed/Refractory Multiple Myeloma: Results from the Phase 1/2 MonumenTAL-1 Study (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_357;
P1
These data show that compressing the total period of step-up dosing had minimal impact on CRS. This has the potential to improve patient experience with tal by shortening the time for which intense CRS monitoring is needed, including inpatient/hospital-based monitoring.
- Carvykti (ciltacabtagene autoleucel) / J&J
Comparative Efficacy of Cilta-Cel vs Approved Comparator Treatments for Patients With Relapsed/Refractory Multiple Myeloma With 1 (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_356;
This has the potential to improve patient experience with tal by shortening the time for which intense CRS monitoring is needed, including inpatient/hospital-based monitoring. Introduction: In the phase 3 CARTITUDE-4 trial, ciltacabtagene autoleucel (cilta-cel) prolonged progression-free survival (PFS) vs standard of care (SOC) (HR [weighted], 0.26; P< 0.0001; HR [unweighted], 0.40; P< 0.0001) in patients with lenalidomide (len)-refractory multiple myeloma (MM) and 1
- Tecvayli (teclistamab-cqyv) / Genmab, J&J, Talvey (talquetamab-tgvs) / J&J
Bispecific antibodies improve outcomes in patients with relapsed or refractory multiple myeloma after CAR-T cell therapy (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_355;
Both agents might overcome the dismal prognosis of EMD relapse. Final analyses including subgroups will be presented at the meeting.
- anitocabtagene autoleucel (CART-ddBCMA) / Arcellx, Gilead
iMMagine-3: A Phase 3, Randomized Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel (Anito-Cel) With Standard of Care in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_350;
P2, P3
Final analyses including subgroups will be presented at the meeting. Before randomization, investigators will select one of the following SOC regimens: pomalidomide (P), bortezomib (V), and dexamethasone (d; PVd); daratumumab (D), P, and d (DPd); carfilzomib (K), D, and d (KDd); or K and d (Kd)...Pts in the anito-cel arm will undergo leukapheresis and optional bridging therapy (with the selected SOC regimen at discretion of the investigator) followed by lymphodepleting chemotherapy (fludarabine 30 mg/m2/d and cyclophosphamide 300 mg/m2/d for 3 d) and one infusion of anito-cel (115
- Talvey (talquetamab-tgvs) / J&J
Talquetamab vs Real-World Physician's Choice in Patients With Relapsed/Refractory Multiple Myeloma and Prior B-Cell Maturation Antigen Therapy: Analyses of MonumenTAL-1 vs LocoMMotion/MoMMent (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_349;
P, P1, P2
Before randomization, investigators will select one of the following SOC regimens: pomalidomide (P), bortezomib (V), and dexamethasone (d; PVd); daratumumab (D), P, and d (DPd); carfilzomib (K), D, and d (KDd); or K and d (Kd)...Pts in the anito-cel arm will undergo leukapheresis and optional bridging therapy (with the selected SOC regimen at discretion of the investigator) followed by lymphodepleting chemotherapy (fludarabine 30 mg/m2/d and cyclophosphamide 300 mg/m2/d for 3 d) and one infusion of anito-cel (115 These analyses demonstrate clinical benefit and superior efficacy of talquetamab vs RWPC for ORR, PFS, and OS, and highlight talquetamab as a novel, highly effective tx option for pts with TCE RRMM and prior BCMA TCR exposure.
- Tecvayli (teclistamab-cqyv) / Genmab, J&J
Teclistamab in real life: Can we shorten the ramp-up ? (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_348;
The rates of CRS in Gp2 was low compared to the Gp1 and occured at D3 or less frequently at D5 i.e. one day less CRS. Moreover, shortened Ramp-up do not compromise pts outcome and toxicity.
- Abecma (idecabtagene vicleucel) / BMS, 2seventy bio, Tecvayli (teclistamab-cqyv) / Genmab, J&J, Carvykti (ciltacabtagene autoleucel) / J&J
Characteristics of Clinicopathological Features of 17 Patients Who had Relapsed Myeloma after Anti-BCMA CAR-T Therapy (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_346;
Moreover, shortened Ramp-up do not compromise pts outcome and toxicity. Patients who were treated with ide-cel (Abecma
- Tecvayli (teclistamab-cqyv) / Genmab, J&J, Talvey (talquetamab-tgvs) / J&J
Can Bispecific T Cell Engagers for Multiple Myeloma be Safely Administered in The Community? A Single Center Experience (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_335;
Post-injection monitoring may be reduced without increased incidence of CRS-related toxicities. Our monitoring guide may serve as a model for the safe administration of T&T in CIC.
- Talvey (talquetamab-tgvs) / J&J
Real world Experience of Talquetamab in relapsed refractory Myeloma, First report from the IMWG consortium (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_334;
This may be in part due to a higher proportion receiving prior immunotherapy thereby accounting for higher rates of CMV subsequently. The high incidence of oral toxicity and dysgeusia described here suggests that optimal management of these side effects is key in maintaining patients on TAL.
- Tecvayli (teclistamab-cqyv) / Genmab, J&J
Real-world analysis of teclistamab treatment for relapsed refractory multiple myeloma in two Belgian university hospitals (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_332;
Tec showed a similar efficacy and safety profile in the real-world setting as in the pivotal trial and other real-world reports, with the exception of a higher ICANS rate, which is difficult to interpret due to several confounding factors. Of note, one patient with prior talquetamab exposure still had at least 12.6 months of VGPR at data cutoff.
- alnuctamab (CC-93269) / BMS
Low infection rates in patients (pts) with relapsed/refractory myeloma (RRMM) treated with alnuctamab (ALNUC) in a setting of infection reduction strategies (IRS) and less frequent dosing (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_330;
P1
Of note, one patient with prior talquetamab exposure still had at least 12.6 months of VGPR at data cutoff. IRS included exclusion of pts with respiratory viruses and prophylaxis against bacteria (eg, levofloxacin; C1